References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
- Society AC. Survival rate for kidney cancer by stage 2017. Available from: https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/survival-rates.html
- Bazzi WM, Sjoberg DD, Feuerstein MA, et al. Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. J Urol. 2015;193:1911–1916.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - melanoma 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - colon cancer 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - breast cancer 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys. 1996;34:251–266.
- Tunio MA, Hashmi A, Rafi M. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncology: Official Journal Eur Soc Med Oncol. 2010;21:1839–1845.
- Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (New York, NY). 1993;260:1317–1320.
- Rini BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer. 2009;115:2306–2312.
- Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013;39:709–719.
- U.S. Food & Drug Administration. Approval letter for axitinib 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202324s000ltr.pdf
- U.S. Food & Drug Administration. Approval letter for cabozantinib 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/208692Orig1s000ltr.pdf
- U.S. Food & Drug Administration. Approval letter for lenvatinib - efficacy, new indication 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/206947Orig1s003ltr.pdf
- U.S. Food & Drug Administration. Approval letter for sorafenib 2005. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021923ltr.pdf
- U.S. Food & Drug Administration. Approval letter for sunitinib 2006. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_Approv.pdf
- U.S. Food & Drug Administration. Approval letter for everolimus 2009. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022334s000ltr.pdf
- U.S. Food & Drug Administration. Approval letter for temsirolimus 2007. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/022088s000ltr.pdf
- U.S. Food & Drug Administration. Approval letter for bevacizumab 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s301lbl.pdf
- Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
- Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63–67.
- Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2001;19:1649–1657.
- Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395–2400.
- Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663–1671.
- Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2004;22:3316–3322.
- Pichler M, Hutterer GC, Chromecki TF, et al. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol. 2011;186:1773–1777.
- Ong FS, Das K, Wang J, et al. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn. 2012;12:593–602.
- Brooks SA, Brannon AR, Parker JS, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol. 2014;66:77–84.
- Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer. 2010;1:152–163.
- Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 2015;16:676–685.
- Ho TH, Kapur P, Eckel-Passow JE, et al. Multicenter validation of enhancer of Zeste homolog 2 expression as an independent prognostic marker in localized clear cell renal cell carcinoma. J Clin Oncol. 2017;35:3706–3713.
- Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994;12:1572–1576.
- Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696.
- Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21:1214–1222.
- Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133–3140.
- Passalacqua R, Caminiti C, Buti S, et al. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-alpha) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). J Immunotherapy. 2014;37:440–447.
- Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 2002;20:395–425.
- Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363:594–599.
- Jonasch E, Wood C, Tamboli P, et al. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008;98:1336–1341.
- Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372:145–154.
- Amin A, Dudek AZ, Logan TF, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunotherapy Cancer. 2015;3:14.
- Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008–2016.
- Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246–2254.
- Chamie K, Donin NM, Klopfer P, et al. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncology. 2017;3:913–920.
- Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2017;35: 3916-3923..
- U.S. Food & Drug Administration. Approval letter for sunitinib - efficacy, new indication 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021938Orig1s033ltr.pdf
- Bex A. Adjuvant sunitinib in renal cell carcinoma: from evidence to recommendation. Ann Oncol. 2017;28:682–684.
- Porta C, Chiellino S. ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. Ann Transl Med. 2016;4:S14.
- Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2010;28:475–480.
- Suttle AB, Ball HA, Molimard M, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111:1909–1916.
- Verheijen RB, Bins S, Mathijssen RH, et al. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin Cancer Res. 2016;22:5738–5746.
- SEJ Pharmaceuticals. Adjuvant axitinib therapy of renal cell cancer in high risk patients (ATLAS) (NCT01599754) 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT01599754?term=NCT01599754&rank=1
- Southwest Oncology Group. S0931, everolimus in treating patients with kidney cancer who have undergone surgery (EVEREST)(NCT01120249) 2010. Available from: https://clinicaltrials.gov/ct2/show/NCT01120249?term=NCT01120249&rank=1
- Medical Research Council. Sorafenib in treating patients at risk of relapse undergoing surgery to remove kidney cancer (NCT00492258) 2007. Available from: https://clinicaltrials.gov/ct2/show/NCT00492258?term=NCT00492258&rank=1
- La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Reviews Clin Oncology. 2011;8:587–596.
- Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Reviews Immunol. 2016;16:599–611.
- Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537–1544.
- Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
- Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76.
- National Cancer Institute. Nivolumab in treating patients with localized kidney cancer undergoing nephrectomy (PROSPER)(NCT03055013) 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03055013?term=NCT03055013&rank=1
- Hoffmann-LaRoche. A study of atezolizumab as adjuvant therapy in participants with renal cell carcinoma (RCC) at high risk of developing metastasis following nephrectomy (IMmotion010) (NCT03024996) 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03024996?term=NCT03024996&rank=1
- Bristol-Myers Squibb. A Study comparing the combination of nivolumab and ipilimumab versus placebo in participants with localized renal cell carcinoma (CheckMate 914) 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03138512?term=NCT03138512&rank=1
- Merck Sharp & Dohme Corp. Safety and efficacy study of pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy (MK-3475-564/KEYNOTE-564) (NCT03142334) 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03142334?term=NCT03142334&rank=1
- Zhang W, Ni M, Su Y, et al. MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. European Urology Focus. 2016. http://dx.doi.org/10.1016/j.euf.2016.09.007. In press.
- Kowalik CG, Palmer DA, Sullivan TB, et al. Profiling microRNA from nephrectomy and biopsy specimens: predictors of progression and survival in clear cell renal cell carcinoma. BJU Int. 2017;120:428–440.
- Xu F, Xu L, Wang Q, et al. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med. 2015;8:14595–14603.
- Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 2012;187:1548–1554.
- Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014;66:874–880.
- James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int. 2009;103:464–469.
- Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539:112–117.